Related Experiment Video

Updated: May 9, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation

Chris Cannon1, Michael D Ezekowitz, Christopher Granger

  • 1Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.

The American Journal of Cardiology
|August 6, 2013
PubMed

Insights

Atrial fibrillation significantly increases stroke risk, necessitating better patient identification and management. This educational webcast explores antithrombotic therapies and physician decision-making for anticoagulation in atrial fibrillation patients.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation is a common arrhythmia affecting over 2.66 million Americans, significantly increasing stroke and mortality risk.
  • Approximately 15-25% of ischemic strokes in the US are linked to atrial fibrillation, highlighting a critical public health concern.
  • Managing atrial fibrillation involves addressing challenges in risk identification, guideline adherence, comorbidity control, and patient compliance.

Purpose of the Study:

  • To discuss the current landscape of antithrombotic therapies for atrial fibrillation.
  • To review new anticoagulant options and factors influencing their clinical use.
  • To provide insights into clinical decision-making and expert lessons for managing anticoagulation in atrial fibrillation.

Main Methods:

  • This content is based on an educational webcast format.
  • Expert faculty discuss clinical decision-making and lessons learned.
  • The webcast reviews current antithrombotic therapies and new anticoagulants.

Main Results:

  • Atrial fibrillation poses a substantial risk for thromboembolic events, including stroke.
  • Effective management requires addressing multiple challenges, from patient identification to treatment adherence.
  • Physician factors significantly influence the utilization of anticoagulation in atrial fibrillation.

Conclusions:

  • Optimizing anticoagulation in atrial fibrillation is crucial for reducing morbidity and mortality.
  • Understanding the complexities of antithrombotic therapy and physician decision-making is essential.
  • Continuous education and adherence to guidelines are vital for improving patient outcomes in atrial fibrillation.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.